Abstract:Background: Glioblastoma (GBM) is the most common primary brain malignancy and has high aggressiveness and a poor prognosis. N6-methyladenosine (m6A) represents the most prevalent methylation modification of lncRNAs and has been shown to play important roles in the pathophysiological processes of tumors. However, the distribution and function of m6A modifications in lncRNAs in GBM tissues have not been fully revealed. Methods: The global depiction of m6A-modified lncRNA expression patterns in GBM tumor tissues was screened via m6A high-throughput sequencing. Gain- and loss-of-function assays were performed to investigate the role of WEE2-AS1 in GBM. Mass spectrometry and RNA-pulldown, RNA immunoprecipitation (RIP), luciferase reporter and coimmunoprecipitation assays were performed to explore the mechanism of m6A-mediated upregulation of WEE2-AS1 expression and the downstream mechanism promoting the malignant progression of GBM. Results: Herein, we report the differential expression profile of m6A-modified lncRNAs in human GBM tissues for the first time. WEE2-AS1 was identified as a novel m6A-modified lncRNA that promotes GBM progression and was post-transcriptionally stabilized by IGF2BP3, an m6A reader. Moreover, we confirmed that WEE2-AS1 promoted RPN2 protein stabilization by preventing CUL2-mediated RPN2 K322 ubiquitination, thereby contributing to GBM malignant progression by activating the PI3K-Akt signaling pathway. In translational medicine, we found that blocking WEE2-AS1 expression improved the therapeutic sensitivity of dasatinib, a central nervous system penetrant that is FDA-approved in GBM. Conclusions: Overall, this work highlights that WEE2-AS1 may serve as a potential prognostic biomarker and therapeutic target in GBM, the knockdown of which significantly improves the efficacy of dasatinib, providing a promising strategy for improving targeted combination therapy for GBM patients.

WDR5-Myc Axis Promotes the Progression of Glioblastoma and Neuroblastoma by Transcriptional Activating CARM1.

Wdr5 Supports An N-Myc Transcriptional Complex That Drives A Protumorigenic Gene Expression Signature In Neuroblastoma

LINC00346 Promotes Pancreatic Cancer Progression Through the CTCF-mediated Myc Transcription

Data from WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma

The N6-methyladenosine-mediated Lncrna WEE2-AS1 Promotes Glioblastoma Progression by Stabilizing RPN2

WDR5 Facilitates Recruitment of N-MYC to Conserved WDR5 Gene Targets in Neuroblastoma Cell Lines

WDR5 facilitates EMT and metastasis of CCA by increasing HIF-1 accumulation in Myc-dependent and independent pathways

WDR5 promotes the tumorigenesis of oral squamous cell carcinoma via CARM1/β-catenin axis

Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation

WD repeat protein 54-mediator of ErbB2-driven cell motility 1 axis promotes bladder cancer tumorigenesis and metastasis and impairs chemosensitivity

Supplementary Dataset 4 from WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma

Overexpression of WD Repeat Domain 5 Associates with Aggressive Clinicopathological Features and Unfavorable Prognosis in Head Neck Squamous Cell Carcinoma.

WDR1 Promotes Cell Growth and Migration and Contributes to Malignant Phenotypes of Non-small Cell Lung Cancer Through ADF/cofilin-mediated Actin Dynamics

MYCN drives oncogenesis by cooperating with the histone methyltransferase G9a and the WDR5 adaptor to orchestrate global gene transcription

WSB1 Regulates C-Myc Expression Through Β-Catenin Signaling and Forms a Feedforward Circuit Promoting the Development of Cancer

Nup54-induced CARM1 nuclear importation promotes gastric cancer cell proliferation and tumorigenesis through transcriptional activation and methylation of Notch2

MYC-targeted WDR4 Promotes Proliferation, Metastasis, and Sorafenib Resistance by Inducing CCNB1 Translation in Hepatocellular Carcinoma

WDR5 Promotes Proliferation and Correlates with Poor Prognosis in Oesophageal Squamous Cell Carcinoma

RUNX1-PDIA5 Axis Promotes Malignant Progression of Glioblastoma by Regulating CCAR1 Protein Expression

High Expression of WDR1 in Primary Glioblastoma is Associated with Poor Prognosis.

Integrative Genomic Analyses Identify WDR12 As a Novel Oncogene Involved in Glioblastoma.